PureTech Health plc (“PureTech” or the “Company”, LSE: PRTC), a science-driven healthcare company seeking to develop disruptive solutions to address unmet medical needs and improve the lives of patients, is pleased to note that Company co-founder board member Dr. Robert Langer today is accepting the Queen Elizabeth Prize for Engineering (“QEPrize”), the world’s largest engineering prize, from Her Majesty the Queen in recognition of his revolutionary advances and leadership in engineering at the interface with chemistry and medicine.
Dr. Robert Langer, FREng, is a co-founder and Board member of PureTech. He is also one of 13 Institute Professors at the Massachusetts Institute of Technology (MIT), the highest honour that can be awarded to a faculty member. His research laboratory is the largest academic biomedical engineering lab in the world with over 100 researchers.
Dr. Langer has won an array of prizes and awards, including the Charles Stark Draper Prize (2002), the 2008 Millennium Prize, the 2013 Wolf Prize, and the 2014 Kyoto Prize. He is one of only 4 living individuals to have received both the United States National medal of science and the United States National medal of technology and innovation. He was named as one of the 25 most important individuals in biotechnology by Forbes Magazine (1999) and Bio World (1990), and as one of the 100 most important people in America (America’s Best) by Time magazine (2001).
The QEPrize is a global prize that celebrates the engineers responsible for a ground-breaking innovation that has been of global benefit to humanity. In this case, the Queen Elizabeth Prize committee stated that “hundreds of millions of people a year across the world benefit from the technologies that rest on the work of Robert Langer”.
Daphne Zohar, CEO of PureTech, commented: “On behalf of everyone at PureTech, I want to congratulate Bob on receiving the Queen Elizabeth Prize for Engineering in recognition of his work on controlled release large molecule drug delivery. His ground-breaking work has had a far-reaching impact, and we are delighted to have access to his knowledge and expertise as a co-founder and Board member of PureTech.”
About PureTech Health
PureTech Health (PureTech Health plc, PRTC.L) is a cross-disciplinary healthcare company, developing innovative products that could potentially improve the lives of billions of patients. PureTech has a pipeline of 12 operating companies, seven of which are “growth stage” with external validation including strategic partnerships, outside funding, proof-of-concept and/or peer review in prestigious scientific journals. PureTech also has a pipeline of ten “concept phase” initiatives resulting from review of more than 650 ideas annually. PureTech is focused on areas including immune and inflammatory disorders; cognitive and psychiatric disorders; diabetes and obesity; oncology; and infectious diseases, and has over 110 patents and patent applications. PureTech’s leading team and board, along with an advisory network of more than 50 expert founder-scientists and advisors across multiple disciplines, gives PureTech access to potentially ground-breaking science and technological innovation. For more information, visit http://www.puretechhealth.com/ and connect with us on Twitter.
Enquiries:
PureTech
Julie DiCarlo, Senior Vice President, Communications
and Investor Relations
+1 617 456 0032
FTI Consulting (Communications adviser to PureTech)
Ben Atwell
Matthew Cole
+44 (0) 20 3727 1000
Help employers find you! Check out all the jobs and post your resume.
